15862-50-7

Basic information

• Product Name: 3-Bromo-2-methoxy-5-nitropyridine
• Synonyms: 3-BROMO-2-METHOXY-5-NITROPYRIDINE;2-Methoxy-3-Bromo-5-Nitropyridine
• CAS NO: 15862-50-7
• Molecular Formula: C₆H₅BrN₂O₃
• Molecular Weight: 233.02
• Product Categories: Pyridine;Pyridines;Heterocyclic Compounds;Bases & Related Reagents;Heterocycles;Nucleotides;Boronic Acid;Pyridine Series
• Mol File: 15862-50-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 89°C
• Boiling Point: 285 °C at 760 mmHg
• Flash Point: 126.1 °C
• Appearance: Light yellow cryst.
• Density: 1.73 g/cm³
• Vapor Pressure: 0.00496mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -2.99±0.20(Predicted)
• CAS DataBase Reference: 3-Bromo-2-methoxy-5-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-methoxy-5-nitropyridine(15862-50-7)
• EPA Substance Registry System: 3-Bromo-2-methoxy-5-nitropyridine(15862-50-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 15862-50-7(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow Cryst

InChI:InChI=1/C6H5BrN2O3/c1-12-6-5(7)2-4(3-8-6)9(10)11/h2-3H,1H3

Upstream product

• 5470-17-7 3-bromo-2-chloro-5-nitropyridine 
• 124-41-4 sodium methylate 
• 15862-33-6 3-bromo-2-hydroxy-5-nitropyridine 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 67-56-1 methanol 

Downstream Products

• 1301610-84-3 tert-butyl (1-(4-((2-methoxy-5-nitropyridin-3-yl)ethynyl)phenyl)cyclobutyl)carbamate 
• 1093951-75-7 3-bromo-2,5-dimethoxypyridine 
• 1299312-97-2 5-bromo-6-methoxypyridin-3-ol 
• 1299312-98-3 4-chloro-2-({2,5-dimethoxypyrid-3-yl}carbonyl)aniline 
• 1299312-99-4 N-formyl-4-chloro-2-({2,5-dimethoxypyrid-3-yl}carbonyl)aniline 

Relevant articles and documents

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511

Replacement of the piperazine sulfonamide portion of the PI3Kα inhibitor AMG 511 (1) with a range of aliphatic alcohols led to the identification of a truncated gem-dimethylbenzylic alcohol analog, 2-(5-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)amino)pyridin-3-yl)propan-2-ol (7). This compound possessed good in vitro efficacy and pharmacokinetic parameters and demonstrated an EC50 of 239 ng/mL in a mouse liver pharmacodynamic model measuring the inhibition of hepatocyte growth factor (HGF)-induced Akt Ser473 phosphorylation in CD1 nude mice 6 h post-oral dosing.

Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists

The present invention is directed to certain novel compounds represented by structural formula I: STR1 or a pharmaceutically acceptable salt thereof, wherein R 3, R 6, R 7, R 8, R 11, R 12, R 13, A, m, n and the dashed lines are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.